Zymeworks Inc. Common Stock Total Liabilities

Latest as of September 2025: $77.20 Million USD

Zymeworks Inc. Common Stock total liabilities. Based on the latest financial reports, Zymeworks Inc. Common Stock (ZYME) has total liabilities worth $77.20 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Zymeworks Inc. Common Stock liquidity resilience to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Zymeworks Inc. Common Stock (2014–2024)

Total liabilities of Zymeworks Inc. Common Stock from 2014 to 2024. This chart illustrates how Zymeworks Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. Explore long-term investment intensity of Zymeworks Inc. Common Stock to see how much of total assets are deployed in long-term investments.

Zymeworks Inc. Common Stock Competitors by Total Liabilities

The table below lists competitors of Zymeworks Inc. Common Stock ranked by their total liabilities.

Company	Country	Total Liabilities
Jiangsu Toland Alloy Co Ltd SHE:300855	China	CN¥1.34 Billion
Aerospace Auto SHG:600151	China	CN¥2.15 Billion
Melco Resorts & Entertainment Ltd NASDAQ:MLCO	USA	$8.70 Billion
OVH Groupe SAS PA:OVH	France	€1.73 Billion
Guangdong Mingyang Electric Co. Ltd. A SHE:301291	China	CN¥4.61 Billion
Fidelis Insurance Holdings Limited NYSE:FIHL	USA	$11.46 Billion
Flight Centre Travel Group Ltd AU:FLT	Australia	AU$3.47 Billion
Sopharma AD WAR:SPH	Poland	zł1.04 Billion

Liability Composition Analysis (2014–2024)

This chart breaks down Zymeworks Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Zymeworks Inc. Common Stock total assets.

Liquidity & Leverage Metrics

Zymeworks Inc. Common Stock Total Liabilities Ratios Explained

Zymeworks Inc. Common Stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric	Value	Description
Current Ratio	6.94	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.24	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.19	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Zymeworks Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Zymeworks Inc. Common Stock (2014–2024)

The table below shows the annual total liabilities of Zymeworks Inc. Common Stock from 2014 to 2024.

Year	Total Liabilities	Change
2024-12-31	$124.32 Million	+7.11%
2023-12-31	$116.07 Million	-25.48%
2022-12-31	$155.77 Million	+11.23%
2021-12-31	$140.04 Million	+9.02%
2020-12-31	$128.45 Million	+4.84%
2019-12-31	$122.52 Million	+91.82%
2018-12-31	$63.87 Million	+311.37%
2017-12-31	$15.53 Million	-81.73%
2016-12-31	$84.99 Million	+1631.02%
2015-12-31	$4.91 Million	-54.97%
2014-12-31	$10.90 Million	--

About Zymeworks Inc. Common Stock

NASDAQ:ZYME USA Biotechnology

Market Cap

$2.32 Billion

Market Cap Rank

#6340 Global

#2020 in USA

Share Price

$30.94

Change (1 day)

+2.69%

52-Week Range

$16.46 - $31.05

All Time High

$56.81